On August 17, 2009
New IPO Window: Fragile, Handle with Care, Remember DOVP
With initial public offerings priced last week by Cumberland Pharmaceuticals and Emdeon, it looks like only a matter of time before the true biotech IPOs. But buy-siders, venture capitalists and even bankers are worried about the wrong candidates ruining everyone’s fun.
0 Comments